Ang II-Induced Cardiac Hypertrophy Mouse Model
Objective: Test pharmacological inhibition of miR-21* in a mouse model of Ang II-induced cardiac hypertrophy to determine if miR-21* inhibition attenuates pathological cardiac remodeling
Gather these items before starting the experiment. Check off items as you prepare.
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Establish Ang II-induced cardiac hypertrophy mouse model
Induce cardiac hypertrophy in mice using Angiotensin II treatment
Note: This is the disease model used to test miR-21* inhibition
View evidence from paper
“Pharmacological inhibition of miR-21* in a mouse model of Ang II–induced cardiac hypertrophy attenuated pathology”
Administer pharmacological miR-21* inhibitor
Treat mice with pharmacological inhibitor of miR-21* in the context of Ang II-induced cardiac hypertrophy
Note: Treatment designed to test whether miR-21* inhibition can attenuate pathological cardiac remodeling
View evidence from paper
“Pharmacological inhibition of miR-21* in a mouse model of Ang II–induced cardiac hypertrophy attenuated pathology”
Assess cardiac pathology
Evaluate cardiac hypertrophy and fibrosis outcomes following miR-21* inhibition treatment
Note: Pathology assessment to determine if miR-21* inhibition attenuates disease phenotype
View evidence from paper
“Pharmacological inhibition of miR-21* in a mouse model of Ang II–induced cardiac hypertrophy attenuated pathology”